Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort.

Discov Oncol · 2025 · PMC12176700 · PMID 40533655

Europe PMC DOI

hedged sentence

0.2230

closest p · 4.5× alpha

0.2230

boldest claim

The sentences

did not reach statistical significanceP = 0.223not close (p > 0.1)

15.1%), though this difference did not reach statistical significance ( P = 0.223).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.